Therapeutic neuroprotective agents for amyotrophic lateral sclerosis

RS Pandya, H Zhu, W Li, R Bowser… - Cellular and molecular …, 2013 - Springer
Amyotrophic lateral sclerosis (ALS) is a fatal chronic neurodegenerative disease whose
hallmark is proteinaceous, ubiquitinated, cytoplasmic inclusions in motor neurons and …

[HTML][HTML] Amyotrophic lateral sclerosis: drug therapy from the bench to the bedside

SB Gibson, MB Bromberg - Seminars in neurology, 2012 - thieme-connect.com
Amyotrophic lateral sclerosis (ALS) is an unrelenting progressive neurodegenerative
disease causing progressive weakness, ultimately leading to death. Despite aggressive …

Diagnosis, pathogenesis and therapeutic targets in amyotrophic lateral sclerosis

J Costa, C Gomes… - CNS & Neurological …, 2010 - ingentaconnect.com
Amyotrophic Lateral Sclerosis (ALS) is a fatal neurodegenerative disease of the motor
system. The diagnosis is clinical, but additional investigations such as electromyography …

Potential therapeutic drugs and methods for the treatment of amyotrophic lateral sclerosis

G Yacila, Y Sari - Current medicinal chemistry, 2014 - ingentaconnect.com
Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disorder caused by damage of
motoneurons leading to paralysis state and long term disability. Riluzole is currently the only …

Current and prospective disease-modifying therapies for amyotrophic lateral sclerosis

JA Morren, N Galvez-Jimenez - Expert Opinion on Investigational …, 2012 - Taylor & Francis
Introduction: Amyotrophic lateral sclerosis (ALS) is a devastating illness of unclear etiology
affecting motor neurons. It causes unremitting muscle paralysis, atrophy and death usually …

Molecular insights and therapeutic targets in amyotrophic lateral sclerosis

A Al-Chalabi, VB Tripathi - CNS & Neurological Disorders-Drug …, 2008 - ingentaconnect.com
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease of motor neurons
resulting in progressive paralysis and respiratory failure. About 1 in every 400 people dies of …

The glutamate hypothesis in ALS: pathophysiology and drug development

H Blasco, S Mavel, P Corcia… - Current medicinal …, 2014 - ingentaconnect.com
Amyotrophic lateral sclerosis (ALS) is an age-related neurodegenerative disorder that is
believed to have complex genetic and environmental influences in the pathogenesis, but …

Pharmacotherapy for amyotrophic lateral sclerosis: a review of approved and upcoming agents

SA Johnson, T Fang, F De Marchi, D Neel… - Drugs, 2022 - Springer
Amyotrophic lateral sclerosis (ALS) is a rapidly progressive neurodegenerative disorder
involving loss of upper and lower motor neurons, with most cases ending in death within 3–5 …

Emerging drugs for the treatment of amyotrophic lateral sclerosis: a focus on recent phase 2 trials

A Barp, F Gerardi, A Lizio, VA Sansone… - Expert Opinion on …, 2020 - Taylor & Francis
Introduction Amyotrophic lateral sclerosis (ALS) is a rapidly progressive neurodegenerative
disease involving both upper and lower motor neurons and resulting in increasing disability …

Emerging drugs for amyotrophic lateral sclerosis

AA Habib, H Mitsumoto - Expert opinion on emerging drugs, 2011 - Taylor & Francis
Introduction: Amyotrophic lateral sclerosis (ALS) is a rapidly progressive neurodegenerative
disease that results in increasing disability and that is uniformly fatal. Since its approval in …